Author:
Jafarpour Mehdi,Saberivand Maryam,Saemi Maryam,Sahebari Maryam,Seyedmardani Seyedmostafa,Salesi Mansour,Hosseinpoor Sarah,Faezi Tahereh,Esalatmanesh Kamal,Hajialilo Mehrzad,Kolahi Sousan,Myrfeizi Zahra,Khabbazi Alireza
Abstract
AbstractRelapsing polychondritis (RP) is a systemic immune mediated disease characterized by recurrent episodes of inflammation in various cartilage-rich areas. RP may cause extensive tissue destruction and is associated with significant morbidity and mortality. In this multicenter study, we considered the remission status and long-term outcomes of RP in patients who were followed-up in six referral rheumatology centers in Iran. Outcomes of disease was assessed by remission status and RP induced damage. A total of 29 patients with RP were examined for enrollment in the study, and 26 patients with a minimum follow-up period of 6 months were included in the RP outcome analysis. Median time to control of symptoms and sustained remission were 5 and 23 weeks, respectively. Prednisolone was discontinued in 8 (30.8%) patients and medication-free remission was achieved in 7 (23.1%) patients. Regarding the disease course, 34.6% of patients had a relapsing–remitting course, 42.3% had a monophasic course, and 23.1% had an always-active course. Despite extensive treatment with immunosuppressive medications, RP induced damage was developed in 21 (80.8%) patients. Ear deformity and osteoporosis were the most common RP induced damage. Long-term remission and medications-free remission in RP is accessible. However, RP related damage occur in majority of patients.
Funder
Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences
Publisher
Springer Science and Business Media LLC